Minerva Neurosciences is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker symbol NERV that is dedicated to developing a range of product candidates aimed at treating central nervous system (CNS) diseases. The company's mission is centered around providing improved therapeutic options to transform the lives of patients. Leveraging their extensive domain expertise, Minerva has strategically acquired and in-licensed a portfolio of development-stage proprietary compounds with what they believe to be innovative mechanisms of action.
Founded in 2007, the company operates within the biopharma, biotechnology, and healthcare industries. Their executive management team is comprised of globally recognized specialists in CNS diseases, focusing on addressing substantial unmet medical needs.
Minerva Neurosciences' most recent investment received was an $88.00K Post-IPO Equity investment on 18 December 2019, with the funding provided by MetLife.
